Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nanobiotix S.A. - ADSs (NQ:NBTX)

3.400 -0.180 (-5.03%)
Streaming Delayed Price Updated: 12:45 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nanobiotix S.A. - ADSs

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why Are Nanobiotix Shares Plummeting Today?
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Earnings Scheduled For April 24, 2023
Companies Reporting Before The Bell • Dynex Cap (NYSE:DX) is estimated to report quarterly earnings at $0.17 per share on revenue of $6.99 million. 
Via Benzinga
Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) 
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) 
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix Posts Updated Data For Radiotherapy-Activated Cancer Therapy In Head & Neck Cancer Patients
Via Benzinga
NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer
Data to be discussed during Nanobiotix Q3 Earnings Call at 8:00AM EST 
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3
Multidisciplinary board includes twelve (12) experts from the United States and Europe that will support the development of lead therapeutic candidate NBTXR3 
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Present at the Jefferies London Healthcare Conference
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022
Conference Call and Webcast to be Held at 8:00 AM ET / 2:00 PM CET on November 10, 2022 
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix: Voting Rights and Shares Capital of the Company
From Nanobiotix
Via Business Wire
Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022
From Nanobiotix
Via Business Wire
Earnings Scheduled For September 28, 2022
Companies Reporting Before The Bell • Lilium (NASDAQ:LILM) is expected to report earnings for its second quarter. 
Via Benzinga
Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022
From Nanobiotix
Via Business Wire
Nanobiotix Establishes Recommended Dose For Registrational Study Of Head & Neck Combo Therapy Trial
Nanobiotix (NASDAQ: NBTX) determined the recommended phase 2 dose (RP2D) of the NBTXR3 combo regime for inoperable locoregional recurrent or recurrent and metastatic head and neck squamous cell... 
Via Benzinga
Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy
From Nanobiotix
Via Business Wire
Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024
From Nanobiotix
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.